Beauty

Shiseido to sell China-based Aupres subsidiary to IDG-led consortium

The Japanese cosmetics group is divesting Shiseido Liyuan Cosmetics as part of a profitability and capital-efficiency drive under its 2030 strategy.

Evelina SandbergNovember 19, 20265 min read2 views

A conceptual still life shows a cosmetic jar being passed between abstract corporate symbols, with a factory outline and e-commerce grid in the background.

Shiseido has signed a binding agreement to sell its Chinese subsidiary, Shiseido Liyuan Cosmetics (SLC), to an investor consortium led by Hong Kong-based private equity firm IDG Capital. SLC makes and sells the Aupres brand in China. The financial terms of the transaction were not disclosed.

The deal is expected to close between the fourth quarter of 2026 and the first quarter of 2027, subject to regulatory approvals, including in China. Under the ownership structure, funds managed by IDG Capital will take 95% of the equity through two special purpose vehicles, while a limited partnership enterprise set up mainly by SLC’s new management team will hold the remaining 5%. The transaction includes SLC’s Beijing factory and production equipment.

Joint venture background

SLC was established in 1991 as a joint venture with Beijing Liyuan, a subsidiary of Yiqing Group owned by the Beijing Municipal Government. The company has sold the C-beauty brand Aupres since 1994. With the current joint venture agreement set to expire in December 2026, the parties agreed not to renew it. On September 1, 2026, Shiseido acquired Beijing Liyuan’s 35% stake, giving it full ownership ahead of the sale.

Strategic rationale

The sale is part of Shiseido’s push to improve profitability and capital efficiency under its 2030 Medium-Term Strategy. Shiseido said it wants to drive sustainable growth and strengthen its competitiveness in China by focusing management resources on areas where it enjoys the greatest competitive advantage. The divestment allows the group to concentrate on priority brands and higher-growth opportunities, according to the company.

Shiseido described the China subsidiary as a business that needs continued investment in product innovation and digital capabilities. It also said China remains a strategically important market and an attractive, dynamic market where the competitive landscape continues to evolve amid rapid e-commerce expansion, changing consumer behavior and the emergence of diverse market participants.

Transition support

To ensure a smooth handover, Shiseido will license the intellectual property rights IDG needs to run the business. For a specified period after the transfer, Shiseido will provide ongoing support on new product development, technical assistance for the stable supply of existing products, and continued supply of raw materials and selected products. The company said this collaboration aims to maintain SLC’s innovation capabilities, product quality and business continuity. Shiseido believes independent operation under IDG will support SLC’s sustainable growth and brand value.

Profitability context

The divestment comes days after Shiseido reported a 124.3% jump in core operating profit for the third quarter of 2026, to ¥67.5 billion, or US$422.13 million. The recovery was attributed to restructuring, cost cuts and improved margins rather than strong product demand; like-for-like sales grew 0.7%. Shiseido raised its full-year core operating profit forecast from ¥59 billion, or US$433 million, to ¥87 billion, or US$546 million, on the back of those results.